Bridger Management Has Upped Its Atara Biotherapeutics (ATRA) Position by $2.05 Million; Stock Price Declined; Lucas Capital Management Trimmed Its Hess (HES) Holding as Stock Value Declined

February 17, 2018 - By Migdalia James

Russell Lucas decreased its stake in Hess Corp (HES) by 60.09% based on its latest 2017Q3 regulatory filing with the SEC. Lucas Capital Management sold 15,179 shares as the company’s stock declined 5.45% while stock markets rallied. The hedge fund run by Russell Lucas held 10,082 shares of the integrated oil company at the end of 2017Q3, valued at $473,000, down from 25,261 at the end of the previous reported quarter. Lucas Capital Management who had been investing in Hess Corp for a number of months, seems to be less bullish one the $14.51 billion market cap company. The stock increased 0.26% or $0.12 during the last trading session, reaching $45.65. About 4.51 million shares traded or 2.11% up from the average. Hess Corporation (NYSE:HES) has declined 14.55% since February 17, 2017 and is downtrending. It has underperformed by 31.25% the S&P500.




Roberto Mignone increased its stake in Atara Biotherapeutics Inc (ATRA) by 8.42% based on its latest 2017Q3 regulatory filing with the SEC. Bridger Management Llc bought 128,322 shares as the company’s stock declined 2.88% while stock markets rallied. The hedge fund run by Roberto Mignone held 1.65 million shares of the health care company at the end of 2017Q3, valued at $27.35M, up from 1.52M at the end of the previous reported quarter. Bridger Management Llc who had been investing in Atara Biotherapeutics Inc for a number of months, seems to be bullish on the $1.71 billion market cap company. The stock decreased 3.51% or $1.65 during the last trading session, reaching $45.4. About 810,307 shares traded. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has declined 7.28% since February 17, 2017 and is downtrending. It has underperformed by 23.98% the S&P500.

Bridger Management Llc, which manages about $3.11B and $1.67 billion US Long portfolio, decreased its stake in Facebook Inc (NASDAQ:FB) by 95,177 shares to 226,328 shares, valued at $38.67M in 2017Q3, according to the filing. It also reduced its holding in Post Hldgs Inc (NYSE:POST) by 12,648 shares in the quarter, leaving it with 1.16 million shares, and cut its stake in Charter Communications Inc N.

Since August 15, 2017, it had 0 buys, and 13 selling transactions for $4.45 million activity. Haqq Christopher had sold 7,604 shares worth $112,159. Shares for $140,802 were sold by Soffer Gad. On Tuesday, August 15 the insider Clark Mitchall G. sold $43,291. $900,815 worth of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) was sold by MCGRATH JOHN on Thursday, January 11. Gallagher Carol Giltner had sold 1,184 shares worth $16,931 on Tuesday, August 15.

Investors sentiment increased to 1.54 in Q3 2017. Its up 0.26, from 1.28 in 2017Q2. It improved, as 8 investors sold ATRA shares while 16 reduced holdings. 9 funds opened positions while 28 raised stakes. 26.16 million shares or 3.51% more from 25.27 million shares in 2017Q2 were reported. Dekabank Deutsche Girozentrale accumulated 9,200 shares or 0% of the stock. Old West Invest Limited Liability, California-based fund reported 20,895 shares. Vanguard reported 918,150 shares stake. Rhumbline Advisers owns 31,598 shares for 0% of their portfolio. Camber Capital Management Limited Liability Co has 0.56% invested in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Credit Suisse Ag invested in 25,582 shares. Arrowmark Colorado Holdings Ltd Liability Corporation holds 2.78 million shares or 0.52% of its portfolio. Moreover, Harbourvest Ptnrs Ltd Limited Liability Company has 0.11% invested in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Mgmt Corp holds 39,330 shares or 0.01% of its portfolio. Bank Of America Corp De holds 0% of its portfolio in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 200,364 shares. Tiverton Asset Mgmt Limited Liability Company invested in 0.03% or 28,166 shares. Parametric Port Associates Ltd Limited Liability Company holds 0% or 30,941 shares in its portfolio. Raymond James Assoc invested 0% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Deutsche Retail Bank Ag invested 0% of its portfolio in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Tiaa Cref Investment Mngmt Ltd Liability accumulated 63,812 shares.

Among 7 analysts covering Atara Biotherapeutics (NASDAQ:ATRA), 5 have Buy rating, 1 Sell and 1 Hold. Therefore 71% are positive. Atara Biotherapeutics had 21 analyst reports since September 9, 2015 according to SRatingsIntel. The stock of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has “Buy” rating given on Monday, October 24 by Jefferies. The company was upgraded on Wednesday, January 3 by Citigroup. As per Thursday, February 15, the company rating was downgraded by Citigroup. The firm earned “Sell” rating on Thursday, September 15 by Goldman Sachs. The stock has “Buy” rating by Canaccord Genuity on Tuesday, January 30. The stock of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) earned “Market Outperform” rating by JMP Securities on Tuesday, December 15. The stock of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) earned “Neutral” rating by Goldman Sachs on Wednesday, November 18. The rating was downgraded by Citigroup on Tuesday, December 15 to “Sell”. The stock has “Buy” rating by Jefferies on Thursday, June 22. William Blair initiated the stock with “Outperform” rating in Friday, October 9 report.

Among 22 analysts covering Hess Corp. (NYSE:HES), 9 have Buy rating, 2 Sell and 11 Hold. Therefore 41% are positive. Hess Corp. had 62 analyst reports since July 22, 2015 according to SRatingsIntel. The stock has “Outperform” rating by Wells Fargo on Friday, May 5. Credit Suisse upgraded the stock to “Neutral” rating in Monday, February 12 report. The stock of Hess Corporation (NYSE:HES) has “Hold” rating given on Friday, September 1 by BMO Capital Markets. The rating was maintained by Piper Jaffray with “Buy” on Tuesday, February 6. Citigroup maintained it with “Neutral” rating and $49 target in Friday, July 21 report. The firm has “Hold” rating by BMO Capital Markets given on Friday, July 28. The stock has “Overweight” rating by JP Morgan on Thursday, December 8. The firm earned “Equal Weight” rating on Tuesday, January 12 by Barclays Capital. The rating was downgraded by J.P. Morgan to “Sell” on Friday, December 15. Societe Generale upgraded the shares of HES in report on Friday, July 31 to “Buy” rating.

Investors sentiment decreased to 0.88 in Q3 2017. Its down 0.12, from 1 in 2017Q2. It is negative, as 43 investors sold HES shares while 162 reduced holdings. 48 funds opened positions while 133 raised stakes. 254.48 million shares or 1.67% more from 250.30 million shares in 2017Q2 were reported. Capital Ww, a California-based fund reported 6.38M shares. Hancock Holding invested in 0.01% or 4,339 shares. 159 were accumulated by Tradewinds Capital Mngmt Limited Liability Corp. First Republic Mgmt owns 7,245 shares or 0% of their US portfolio. Mayo Investment Advisers Limited Liability holds 5.69% of its portfolio in Hess Corporation (NYSE:HES) for 264,303 shares. Campbell & Adviser Limited Liability Corp reported 7,174 shares stake. Conning, a Connecticut-based fund reported 7,617 shares. Orrstown Serv stated it has 32 shares or 0% of all its holdings. Bridgewater Associate Ltd Partnership stated it has 16,357 shares or 0.01% of all its holdings. Nwq Invest Mgmt Ltd Llc holds 1.01% or 1.75M shares in its portfolio. Lmr Limited Liability Partnership reported 16,448 shares stake. Geode Capital Mngmt Ltd Liability Corporation has invested 0.05% of its portfolio in Hess Corporation (NYSE:HES). State Treasurer State Of Michigan owns 82,005 shares for 0.03% of their portfolio. Price T Rowe Inc Md, a Maryland-based fund reported 22.26M shares. 15,351 were accumulated by Walleye Trading Limited.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.